These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 7624708)

  • 21. Market exclusivity after a prescription to nonprescription drug switch: striking the right balance between innovation and competition.
    Kraushaar KJ
    Food Drug Law J; 1999; 54(2):243-4. PubMed ID: 11758581
    [No Abstract]   [Full Text] [Related]  

  • 22. FDA considers OTC drug labeling reform.
    Am Pharm; 1995 Nov; NS35(11):5-6. PubMed ID: 8533722
    [No Abstract]   [Full Text] [Related]  

  • 23. FDA OTC advisory group needs practitioners.
    Jellin JM
    Am Pharm; 1993 Apr; NS33(4):4, 90. PubMed ID: 8475854
    [No Abstract]   [Full Text] [Related]  

  • 24. OTC drowsy or legend drowsy.
    Archambault GF
    Hosp Formul; 1977 Mar; 12(3):200. PubMed ID: 10235808
    [No Abstract]   [Full Text] [Related]  

  • 25. Abuse of OTC medications, prescription drugs raises concern.
    Langford RE
    Occup Health Saf; 2001 Dec; 70(12):8. PubMed ID: 11799566
    [No Abstract]   [Full Text] [Related]  

  • 26. User-friendly labeling for OTC drugs.
    Chase SL
    RN; 1999 Jul; 62(7):93. PubMed ID: 10446641
    [No Abstract]   [Full Text] [Related]  

  • 27. Over-the-counter human drugs; labeling requirements. Food and Drug Administration, HHS. Final rule.
    Fed Regist; 1999 Mar; 64(51):13254-303. PubMed ID: 10557606
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The effect of the Rx-to-OTC switch of loratadine and changes in prescription drug benefits on utilization and cost of therapy.
    Sullivan PW; Nair KV; Patel BV
    Am J Manag Care; 2005 Jun; 11(6):374-82. PubMed ID: 15974556
    [TBL] [Abstract][Full Text] [Related]  

  • 29. OTC labeling reform.
    J Am Pharm Assoc (Wash); 1997; NS37(6):619-20. PubMed ID: 9425787
    [No Abstract]   [Full Text] [Related]  

  • 30. Costs and benefits in switching from Rx to OTC.
    Temin P
    J Health Econ; 1983 Dec; 2(3):187-205. PubMed ID: 10310393
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Report of the Task Force on the future of OTC drugs.
    Collins DE
    Food Drug Law J; 2000; 55(1):27-31. PubMed ID: 12269359
    [No Abstract]   [Full Text] [Related]  

  • 32. Theophylline is off the OTC market. Ephedrine may be next.
    Chase SL
    RN; 1995 Dec; 58(12):79. PubMed ID: 8560184
    [No Abstract]   [Full Text] [Related]  

  • 33. Bar coding: old technology to the rescue.
    Ochs J
    Manag Care; 2003 Jun; 12(6):46-7. PubMed ID: 12854261
    [No Abstract]   [Full Text] [Related]  

  • 34. FDA panel vetoes OTC version of cholesterol drug.
    Walczak IM
    Diabetes Technol Ther; 2000; 2(3):484. PubMed ID: 11467353
    [No Abstract]   [Full Text] [Related]  

  • 35. An overview of over the counter drugs in pregnancy and lactation.
    Das BP; Joshi M; Pant CR
    Kathmandu Univ Med J (KUMJ); 2006; 4(4):545-51. PubMed ID: 18603972
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Over-the-counter medications and self-care.
    Lowe NK; Ryan-Wenger NM
    Nurse Pract; 1999 Dec; 24(12):34-44. PubMed ID: 10635517
    [TBL] [Abstract][Full Text] [Related]  

  • 37. New OTC drug facts label.
    FDA Consum; 2002; 36(4):35. PubMed ID: 12184303
    [No Abstract]   [Full Text] [Related]  

  • 38. Plan B: Politics and values at the FDA, again.
    Dresser R
    Hastings Cent Rep; 2004; 34(6):9-10. PubMed ID: 15704280
    [No Abstract]   [Full Text] [Related]  

  • 39. New warning issued on OTC analgesics.
    Chase SL
    RN; 1999 Mar; 62(3):93. PubMed ID: 10205570
    [No Abstract]   [Full Text] [Related]  

  • 40. OTC status for low-dose lovastatin would have widespread implications.
    Sipkoff M
    Manag Care; 2004 Nov; 13(11):36-40. PubMed ID: 15595400
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.